Search results for "HEPATITIS B"

showing 10 items of 451 documents

Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine Co-administered with a hib conjugate vaccine either as a si…

2004

A combined DTPa-HBV-IPV/Hib vaccine containing diphtheria (D), tetanus (T), acellular pertussis (Pa), hepatitis B (HBV) and types 1, 2 and 3 inactivated polioviruses (IPV) extemporaneously mixed with a conjugated Haemophilus influenzae type b (Hib) vaccine (Group 1) was compared to the DTPa-HBV-IPV and Hib vaccines (Group 2) administered separately at 3, 5 and 11 months of age (n = 440). A microneutralization assay was used to detect antibodies against the 3 polio virus types (cut-off 1:8 dil), RIA for anti-HBs antibodies (cut-off 10 mIU/ml) and ELISA for antibodies against all other vaccine antigens (cut-off: 0.1 IU/ml for anti-tetanus and anti-diphtheria antibodies; 5 El.U/ml for antibodi…

MaleMicrobiology (medical)Vaccination scheduleEnzyme-Linked Immunosorbent AssayAntibodies ViralInjections IntramuscularRisk Assessmentcomplex mixturesConjugate vaccineGermanyConfidence IntervalsmedicineHumansHepatitis B VaccinesVaccines CombinedBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesProbabilityImmunity CellularReactogenicityGeneral Immunology and MicrobiologyTetanusbusiness.industryImmunogenicityDiphtheriaPolysaccharides BacterialVaccinationInfantGeneral MedicineHib Conjugate vaccinemedicine.diseaseAntibodies BacterialVirologyHexavalent combination; DTPa-HBV-IPV combination vaccine; Hib Conjugate vaccineVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesItalyHib vaccineHexavalent combinationImmunologyFemalebusinessDTPa-HBV-IPV combination vaccineFollow-Up StudiesScandinavian Journal of Infectious Diseases
researchProduct

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a mu…

2015

Equipe CHU UB (EA) Pôle MERS CT3 Hors Enjeu ANRS HB04 B-BOOST study group : Hugues Aumaitre (Centre Hospitalier Marechal Joff re, Perpignan, France); Jean-Luc Berger (Centre Hospitalier Universitaire de Reims– Hopital Robert Debre, Reims, France); Alain Devidas (Hopital Gilles de Corbeil–Centre Hospitalier Sud Francilien, Corbeil Essonne, France); Sophie Abgrall (Centre Hospitalier Universitaire Avicenne, Avicenne, France); Olivier Patey (Centre Hospitalier Intercommunal de Villeneuve St Georges, Villeneuve Saint Georges, France); Marie-Christine Drobacheff Thiebaut (Centre Hospitalier Universitaire de Besancon–Hopital Saint Jacques, Besancon, France); Frederic Lucht (Centre Hospitalier Uni…

MalePediatricsefficacyHIV InfectionsBooster doselaw.invention0302 clinical medicineRandomized controlled triallaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesvaccineSingle-Blind Method030212 general & internal medicineVaccines Synthetic0303 health sciencesnumberinfected patientMiddle AgedHepatitis BHepatitis B3. Good healthVaccinationTreatment OutcomeInfectious Diseaseshomosexual man[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesFemaleFranceViral hepatitisAdultmedicine.medical_specialtyHepatitis B vaccineImmunization SecondaryvirusYoung Adult03 medical and health sciencesmedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAgedIntention-to-treat analysis030306 microbiologybusiness.industrymedicine.diseaserateRegimeninjection[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessimpaired response
researchProduct

Immunization status of internationally adopted children in Italy

2006

An increasing number of internationally adopted children is coming to Italy, and their immunization status is unknown. We evaluated the immunization status of such children in Palermo, Italy. We searched for the presence of a BCG scar in 88 children, 49 boys and 39 girls (mean age 76+/-32 months), most of whom (98%) came from Eastern Europe. Presence of BCG scar was observed in 59 (67.1%) of them, included five children without any pre-adoptive medical records. Twenty-three out of 29 children without any evidence of BCG scar were tested by Mantoux. Seven (30.4%) of 23 were tuberculin positive and diagnosed as having latent tuberculosis infection. We also examined immunization status against…

MalePediatricsmedicine.medical_specialtyHealth StatusTuberculinAntibodies ViralMeaslesRubellaMedical RecordsAdoptionmedicineHumansEurope EasternChildVaccinesGeneral VeterinaryGeneral Immunology and MicrobiologyLatent tuberculosisTuberculin TestTetanusbusiness.industryDiphtheriaImmunization.Public Health Environmental and Occupational HealthInfantEmigration and ImmigrationHepatitis Bmedicine.diseaseAntibodies BacterialAdopted childrenInfectious DiseasesItalyImmunizationChild PreschoolImmunologyBCG VaccineMolecular MedicineFemaleImmunizationbusinessVaccine
researchProduct

B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination

2006

MalePediatricsmedicine.medical_specialtyddc:618General VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantVaccination/adverse effectsddc:616.07Diphtheria-Tetanus-acellular Pertussis Vaccines/adverse effectsVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesSudden Infant Death/blood/epidemiologyVaccines Combined/adverse effectsmedicineHumansMolecular MedicineFemaleHepatitis B VaccinesbusinessDiphtheria-Tetanus-Pertussis VaccineSudden infant deathVaccine
researchProduct

Recent insights into the relationship between inflammatory liver diseases and atherosclerosis.

2011

Atherosclerosis is a dynamic process in the human body. Many studies have evaluated atherosclerosis and its relationship with other systems in the body. Our perception of its pathogenesis is evolving with the introduction of new players in the game. It is no longer possible to consider the atherosclerosis as an independent process, unaffected by the liver and its function. Although several tasks performed by the liver, such as lipid metabolism, have been implicated in the pathogenesis of atherosclerosis, the role of other disorders of the liver (autoimmune diseases, viral hepatitis, and cirrhosis) are not fully understood. In this review, the most commonly encountered inflammatory liver di…

MaleRiskHepatitis B virusCirrhosisInflammationHepacivirusBiologyGeneral Biochemistry Genetics and Molecular BiologyAutoimmune DiseasesHepatitisPathogenesisFibrosisPrevalencemedicineHumansInflammationHepatitisCholestasisLiver DiseasesResearchFatty liverLipid metabolismGeneral MedicineAtherosclerosismedicine.diseasehepatitis B hepatitis C hepatitis A inflammation fatty liver atherosclerosisFibrosisFatty LiverLiverImmunologyFemalemedicine.symptomViral hepatitis
researchProduct

Hepatitis B virus reactivation and alemtuzumab therapy

2005

Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immmunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab the…

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaHepatitis B virusHBsAgCD52Antibodies Neoplasmmedicine.medical_treatmenthepatitis B viruAntibodies Monoclonal Humanizedmedicine.disease_causeCampath-1HSettore MED/15 - Malattie Del SanguemedicineHumansAlemtuzumabImmunosuppression TherapyHepatitisHepatitis B virusSettore MED/12 - GastroenterologiaHepatitis B Surface Antigensbusiness.industryacute hepatitiAntibodies Monoclonalvirus diseasesLamivudineImmunosuppressionHematologyGeneral MedicineMiddle AgedHepatitis BHepatitis Bmedicine.diseaseLeukemia Lymphocytic Chronic B-Celldigestive system diseasesLamivudineDNA ViralImmunologyReverse Transcriptase InhibitorsAlemtuzumabFemaleVirus Activationbusinesschronic lymphocytic leukaemiamedicine.drugEuropean Journal of Haematology
researchProduct

Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study

2017

Background and Aim The universal hepatitis B vaccination for infants and 12-year-old adolescents (the latter limited to the first 12 years of application) was launched in Italy in 1991. Twenty-three years later we evaluated the impact of the vaccination campaign on the burden of HBsAg-positive chronic liver diseases (CLD). Material and Methods 513 HBsAg-positive chronic carriers referring to 16 Italian liver units were investigated and compared with HBsAg carriers enrolled in previous surveys. Results The proportion of inactive carriers decreased from 20.0% in 2001 to 3.3% in 2014, while that of cirrhotic patients increased from 22.6 to 33.2%. Regarding the age class 0–33 (fully covered by …

MaleTime FactorsCirrhosisSettore MED/09 - Medicina InternaHbv vaccination0302 clinical medicinechronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccinationMedicine030212 general & internal medicineChildAged 80 and overVaccinationMiddle AgedVaccinationInfectious DiseasesItalyLiverCarrier StateFemale030211 gastroenterology & hepatologyHbsag carrierAdultHepatitis B virusAdolescentYoung Adult03 medical and health sciencesHepatitis B ChronicChronic hepatitisVirologyHumansHBsAg-positive chronic hepatitis clinical presentationHepatitis B Vaccineschronic hepatitis BHepatitis B AntibodiesHBsAg-positive chronic hepatitisAgedHBsAg chronic carrierHBV vaccinationImmunization Programsbusiness.industrychronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; virology; infectious diseasesInfantchronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; Virology; Infectious Diseasesmedicine.diseaseVirologyCross-Sectional StudiesHBsAg chronic carriersMulticenter studyHepatitis b vaccinationHBsAg-positive chronic hepatitibusiness
researchProduct

Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir

2019

Background and Aims: Tenofovir disoproxil fumarate (TDF) is recommended for chronic hepatitis B (CHB) treatment, but it may induce kidney dysfunction whose management is not yet known. This Italian, multicentre, retrospective study aimed to assess the efficacy and safety of switching to entecavir (ETV) patients who developed TDF-associated glomerular and/or tubular dysfunction. Methods: A total of 103 TDF-treated patients were included as follows: age 64 years, 83% male, 49% cirrhotics, 98% with undetectable HBV DNA, 47% with previous lamivudine resistance (LMV-R) and 71% previously treated with adefovir. Twenty-nine (28%) were switched to ETV because estimated glomerular filtration rate (e…

MaleTime FactorsSustained Virologic Responsehepatitis B viruKidneyGastroenterologyhepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitischemistry.chemical_compound0302 clinical medicine80 and overAdefovirChronicAged 80 and overKidneymedicine.diagnostic_testDrug Substitutionhepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitis; HepatologyEntecavirMiddle AgedHepatitis BHepatitis BTreatment Outcomemedicine.anatomical_structureItaly030220 oncology & carcinogenesisFemaleKidney Diseases030211 gastroenterology & hepatologyViral hepatitismedicine.drugAdultmedicine.medical_specialtyGuaninehepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitis; Adult; Aged; Aged 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B Chronic; Humans; Italy; Kidney; Kidney Diseases; Male; Middle Aged; Recovery of Function; Retrospective Studies; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome; Drug Substitutionviral hepatitisRenal functionliverAntiviral Agents03 medical and health sciencesHepatitis B ChronicInternal medicinerenal dysfunctionmedicineHumansliver function testTenofovirAgedRetrospective StudiesCreatinineHepatologybusiness.industryviral hepatitiRecovery of Functionmedicine.diseasechemistryliver function testsbusinessLiver function testshepatitis B virus
researchProduct

Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults.

2007

Response to hepatitis A and B vaccines has been reported to decline with age. This open, prospective, single-site study examined the long-term response to the combined hepatitis A/B vaccine Twinrix in 98 primary responders aged 45-67 years. Levels of antibody against hepatitis A virus (HAV) and hepatitis B surface antigen (HBs) were tested 30 months after initial vaccination. At this stage, all participants remained seropositive for anti-HAV and 70% for anti-HBs. A booster vaccination was offered to those who had responded to the first vaccination but then lost protective levels of anti-HBs. An anamnestic response was observed in all cases.

MaleTwinrixHepatitis A AntibodiesCohort StudiesMedicineHumansHepatitis B VaccinesProspective StudiesVaccines CombinedHepatitis B AntibodiesProspective cohort studyAgedHepatitis A VaccinesHepatitis B Surface AntigensGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryPublic Health Environmental and Occupational Healthvirus diseasesHepatitis AMiddle Agedmedicine.diseaseVirologydigestive system diseasesVaccinationClinical trialInfectious DiseasesImmunologyAntibody Formationbiology.proteinMolecular MedicineFemaleViral diseaseAntibodybusinessImmunologic MemoryCohort studyVaccine
researchProduct

Active immunization status against measles, mumps, rubella, hepatitis B in internationally adopted children, surveyed at the university hospital of P…

2018

Introduction. The internationally adopted child is a fragile subject who often shows an incomplete health documentation, which hinders the complete assessment of health status. Materials and Methods. Between January 2010 and June 2016, at the University Hospital "AOUP P. Giaccone" of Palermo, we reviewed the health documentations of 111 children recently arrived in Italy following the conclusion of the international adoption procedure. 62.2% of the children were male, of various nationalities and with an average age of 7 years (± 3.4). This study aims to detect, in the observed sample, the reliability of the vaccinal documentation and the real acquired immunization. We intend to estimate th…

MaleVaccinesVaccinationImmunization SecondaryInfantReproducibility of ResultsDocumentationEmigration and ImmigrationHepatitis BHospitals UniversityInternationally adopted childrenChild PreschoolImmunoglobulin GVaccine-preventable diseasesHumansFemaleImmunizationChildChild AdoptedMumpsSicilyRubellaMeasles
researchProduct